Literature DB >> 34423177

Antibody Nanocarriers for Cancer Management.

Megan N Dang1, Elise C Hoover1, Mackenzie A Scully1, Eric H Sterin1, Emily S Day1,2,3.   

Abstract

Antibodies are extremely valuable tools in modern medicine due to their ability to target diseased cells through selective antigen binding and thereby regulate cellular signaling or inhibit cell-cell interactions with high specificity. However, the therapeutic utility of freely delivered antibodies is limited by high production costs, low efficacy, dose-limiting toxicities, and inability to cross the cellular membrane (which hinders antibodies against intracellular targets). To overcome these limitations, researchers have begun to develop nanocarriers that can improve antibodies' delivery efficiency, safety profile, and clinical potential. This review summarizes recent advances in the design and implementation of nanocarriers for extracellular or intracellular antibody delivery, emphasizing important design considerations, and points to future directions for the field.

Entities:  

Keywords:  binding affinity; multivalency; nanoparticles; signal cascade interference; targeted antibodies

Year:  2021        PMID: 34423177      PMCID: PMC8373047          DOI: 10.1016/j.cobme.2021.100295

Source DB:  PubMed          Journal:  Curr Opin Biomed Eng        ISSN: 2468-4511


  54 in total

Review 1.  Intracellular delivery of proteins by nanocarriers.

Authors:  Moumita Ray; Yi-Wei Lee; Federica Scaletti; Ruijin Yu; Vincent M Rotello
Journal:  Nanomedicine (Lond)       Date:  2017-03-24       Impact factor: 5.307

Review 2.  The Increasingly Human and Profitable Monoclonal Antibody Market.

Authors:  António L Grilo; A Mantalaris
Journal:  Trends Biotechnol       Date:  2018-06-23       Impact factor: 19.536

3.  pH Impacts the Orientation of Antibody Adsorbed onto Gold Nanoparticles.

Authors:  Guadalupe Ruiz; Kiran Tripathi; Samuel Okyem; Jeremy D Driskell
Journal:  Bioconjug Chem       Date:  2019-03-19       Impact factor: 4.774

4.  Tumor Microenvironment Activated Membrane Fusogenic Liposome with Speedy Antibody and Doxorubicin Delivery for Synergistic Treatment of Metastatic Tumors.

Authors:  Hongzhang Deng; Kun Song; Xuefei Zhao; Yanan Li; Fei Wang; Jianhua Zhang; Anjie Dong; Zhihai Qin
Journal:  ACS Appl Mater Interfaces       Date:  2017-03-10       Impact factor: 9.229

5.  Gold nanoshell bioconjugates for molecular imaging in living cells.

Authors:  Christopher Loo; Leon Hirsch; Min-Ho Lee; Emmanuel Chang; Jennifer West; Naomi Halas; Rebekah Drezek
Journal:  Opt Lett       Date:  2005-05-01       Impact factor: 3.776

6.  Lipocalin 2 promotes breast cancer progression.

Authors:  Jiang Yang; Diane R Bielenberg; Scott J Rodig; Robert Doiron; Matthew C Clifton; Andrew L Kung; Roland K Strong; David Zurakowski; Marsha A Moses
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

7.  Nanoparticle-Mediated Co-Delivery of Notch-1 Antibodies and ABT-737 as a Potent Treatment Strategy for Triple-Negative Breast Cancer.

Authors:  Danielle M Valcourt; Megan N Dang; Mackenzie A Scully; Emily S Day
Journal:  ACS Nano       Date:  2020-02-26       Impact factor: 15.881

8.  Immunonanoshells for targeted photothermal ablation of tumor cells.

Authors:  Amanda R Lowery; André M Gobin; Emily S Day; Naomi J Halas; Jennifer L West
Journal:  Int J Nanomedicine       Date:  2006

9.  Dual complementary liposomes inhibit triple-negative breast tumor progression and metastasis.

Authors:  Peng Guo; Jiang Yang; Daxing Liu; Lan Huang; Gillian Fell; Jing Huang; Marsha A Moses; Debra T Auguste
Journal:  Sci Adv       Date:  2019-03-20       Impact factor: 14.136

10.  A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma.

Authors:  Priya Kumthekar; Caroline H Ko; Tatjana Paunesku; Karan Dixit; Adam M Sonabend; Orin Bloch; Matthew Tate; Margaret Schwartz; Laura Zuckerman; Ray Lezon; Rimas V Lukas; Borko Jovanovic; Kathleen McCortney; Howard Colman; Si Chen; Barry Lai; Olga Antipova; Junjing Deng; Luxi Li; Serena Tommasini-Ghelfi; Lisa A Hurley; Dusten Unruh; Nitya V Sharma; Manoj Kandpal; Fotini M Kouri; Ramana V Davuluri; Daniel J Brat; Miguel Muzzio; Mitchell Glass; Vinod Vijayakumar; Jeremy Heidel; Francis J Giles; Ann K Adams; C David James; Gayle E Woloschak; Craig Horbinski; Alexander H Stegh
Journal:  Sci Transl Med       Date:  2021-03-10       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.